Sanofi-Regeneron $81 Billion Upside on Dupixent Patents to 2037: BI Replay

On Demand

Duration: 30 Minutes

Original Date: May 28, 2026

First name

Last name

Business email

Business phone

Company

Job role

Industry

City

Country or Region

State or Province Optional

Yes, I would like to be contacted by a representative to learn more about Bloomberg's solutions and services.

What are you interested in learning more about?

By submitting this information, I agree to the privacy policy and to learn more about products and services from Bloomberg.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Join BI Patent Specialists and Analysts for a webinar focused on the patent estates of Sanofi-Regeneron’s anti-inflammatory blockbuster, Dupixent. We forecast protection until 2037, not the current consensus expectation of 2031, resulting in additional sales of $81 billion and profit of $41 billion.

Sanofi-Regeneron $81 Billion Upside on Dupixent Patents to 2037: BI Replay

Access a broad range of analysis, research, insight and actionable ideas with Bloomberg webinars.